Clinical trial
Immunogenicity and Safety of Different Doses of Fluzone® Influenza
NCT00253734 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00253734 |
|---|---|
| Title | Immunogenicity and Safety of Different Doses of Fluzone® Influenza |
| Official title | Immunogenicity and Safety of a Split, Inactivated, Trivalent Influenza Vaccine Administered by Intradermal Route Compared to an Intramuscular Vaccination With Fluzone® in Healthy Adults |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Influenza |
| Intervention type | Biological |
| Interventions | Fluzone® (IM), Fluzone® |
| Enrollment | 217 |
| Start date | Nov 1, 2005 |
| Primary completion | Oct 1, 2006 |
| Completion | Nov 1, 2006 |
| First posted | Nov 15, 2005 |
| Last update posted | Jun 3, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: